Most policies still exclude weight-loss medications under general exclusions unless they are part of the treatment of a ...

When I was assigned to write my first story about the blockbuster weight loss drug Ozempic in 2023, I groaned. Yes, weight loss drugs always generate feverish interest, but historically, they’ve both ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...